Global Depression Therapy & Treatment Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022
Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment. Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally. Antidepressants segment consists of big pharmaceuticals companies like Eli Lily, Pfizer, GlaxoSmithKline and Forest Laboratories. All these companies are branded drug manufacturers. Some of the popular drugs produced by these companies are Cymbalta (Eli Lily) and Effexor and Pristiq (Pfizer). The devices market is the fastest growing market segment.
1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2022
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies
1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2022
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies
CHAP 1. EXECUTIVE SUMMARY
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
CHAP 2. MARKET OVERVIEW –DEPRESSION IS A MAJOR CONCERN WORLDWIDE
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression
2.3.5.1. Psychotic Depression
2.3.5.2. Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs
2.4.1.1. Manufacturers
2.4.1.2. Distributors
2.4.1.3. Retailers
2.4.1.4. End-Users
2.4.2. For Devices
2.4.2.1. Manufacturers
2.4.2.2. Distributors
2.4.2.3. End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
CHAP 3. MARKET SEGMENTATION
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs)
3.4.4.1. Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
3.5.1. Cognitive Behavior Therapy (CBT)
3.5.2. Electroconvulsive Therapy (ECT)
3.5.3. Rational emotive behavior therapy (REBT)
3.5.4. Device enabled therapies
3.5.4.1. Transcranial Magnetic Stimulation (TMS) therapy
3.5.4.2. Deep Brain Stimulation
3.5.4.3. Vagus Nerve Stimulator
3.5.4.4. Virtual Reality (VR)
3.5.4.5. Smart phone applications
3.5.5. Other Therapies
3.5.5.1. Ketamine therapy
3.5.6. Special Conditions
3.5.6.1. Antidepressants discontinuation syndrome (ADS)
3.5.6.2. Treatment-resistant depression
3.5.6.3. Rehabilitation centre for depression
3.5.6.4. Rehabilitation programs through VR technology
CHAP 4. DEPRESSION PREVALENCE BY GENDER
4.1. Depression in Men
4.2. Depression in Women
4.2.1. Depression in Elderly is a common phenomenon
CHAP 5. RESURGENT GENERIC DRUGS MARKET DUE TO PATENT EXPIRY
CHAP 6. COMPETITIVE TRENDS, STRATEGIES & MARKET SHARE
6.1. Key Focus on Cost Control Impacting R&D Initiatives
6.2. Partnerships and acquisitions
6.3. Generic drug manufacturers focusing on patent expiration and semi regulated markets
6.4. Market Share Analysis
CHAP 7. GEOGRAPHICAL ANALYSIS
7.1. Devices market is growing in North America, Europe and Asia Pacific
7.2. North America is the highest drug market for depression
7.2.1. US has the largest patient pool for depression drugs & devices
7.2.2. US market is driven by strict regulations
7.2.3. Mental illness is a major disease in Canada
7.3. Depression is a major concern in Europe
7.3.1. almost 16.7 million people suffer from depression in the UK
7.3.2. Regulations in the United Kingdom
7.3.3. France has the highest rate of depression amongst developed nations
7.3.4. Germany has prevalence rate of 4.5-5% for depression
7.3.5. Spain has strict regulations for depression drugs
7.4. Asia Pacific has a strongly emerging generic drugs market
7.4.1. Approx 60% of the population in China is undiagnosed for depression
7.4.2. India has over 10 million people suffering from depression
7.4.3. Financial burden of depression in Japan amounts to nearly $15 billion
7.4.4. Depression is a common occurring health issue in the age group 12-25 years in Australia
CHAP 8. CORPORATE PROFILING
8.1. Pfizer
8.1.1. Overview
8.1.2. Strategic Analysis
8.1.3. SCOT Analysis
8.2. GlaxoSmithKline
8.2.1. Overview
8.2.2. SCOT Analysis
8.3. Forest Laboratories
8.3.1. Overview
8.3.2. SCOT Analysis
8.4. Abbot Laboratories
8.4.1. Overview
8.4.2. SCOT Analysis
8.5. Eli Lilly and Company
8.5.1. Overview
8.5.2. SCOT Analysis
8.6. Merck Sharp &Dohme
8.6.1. Overview
8.6.2. SCOT Analysis
8.7. Sanofi
8.7.1. Overview
8.7.2. SCOT Analysis
8.8. Neuronetics
8.8.1. Overview
8.8.2. SCOT Analysis
8.9. Teva pharmaceuticals Industries
8.9.1. Overview
8.9.2. SCOT Analysis
8.10. Mayo Clinic
8.10.1. Overview
8.10.2. Mayo Clinic product portfolio in depression therapy
8.10.3. SCOT Analysis
8.11. Sun Pharmaceuticals
8.11.1. Overview
8.11.2. SCOT Analysis
8.12. Brainsway
8.12.1. Overview
8.12.2. SCOT Analysis
8.13. Fisher Wallace
8.13.1. Overview
8.13.2. SCOT Analysis
8.14. MagVentures
8.14.1. Overview
8.15. Lundbeck
8.15.1. Overview
8.15.2. Strategic moves
8.15.3. SCOT Analysis
8.16. BoehringerIngelheim GmbH
8.16.1. Overview
8.16.2. SCOT Analysis
8.17. Roche Holding AG
8.17.1. Overview
8.17.2. Strategic Moves
8.17.3. SCOT Analysis
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
CHAP 2. MARKET OVERVIEW –DEPRESSION IS A MAJOR CONCERN WORLDWIDE
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression
2.3.5.1. Psychotic Depression
2.3.5.2. Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs
2.4.1.1. Manufacturers
2.4.1.2. Distributors
2.4.1.3. Retailers
2.4.1.4. End-Users
2.4.2. For Devices
2.4.2.1. Manufacturers
2.4.2.2. Distributors
2.4.2.3. End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
CHAP 3. MARKET SEGMENTATION
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs)
3.4.4.1. Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
3.5.1. Cognitive Behavior Therapy (CBT)
3.5.2. Electroconvulsive Therapy (ECT)
3.5.3. Rational emotive behavior therapy (REBT)
3.5.4. Device enabled therapies
3.5.4.1. Transcranial Magnetic Stimulation (TMS) therapy
3.5.4.2. Deep Brain Stimulation
3.5.4.3. Vagus Nerve Stimulator
3.5.4.4. Virtual Reality (VR)
3.5.4.5. Smart phone applications
3.5.5. Other Therapies
3.5.5.1. Ketamine therapy
3.5.6. Special Conditions
3.5.6.1. Antidepressants discontinuation syndrome (ADS)
3.5.6.2. Treatment-resistant depression
3.5.6.3. Rehabilitation centre for depression
3.5.6.4. Rehabilitation programs through VR technology
CHAP 4. DEPRESSION PREVALENCE BY GENDER
4.1. Depression in Men
4.2. Depression in Women
4.2.1. Depression in Elderly is a common phenomenon
CHAP 5. RESURGENT GENERIC DRUGS MARKET DUE TO PATENT EXPIRY
CHAP 6. COMPETITIVE TRENDS, STRATEGIES & MARKET SHARE
6.1. Key Focus on Cost Control Impacting R&D Initiatives
6.2. Partnerships and acquisitions
6.3. Generic drug manufacturers focusing on patent expiration and semi regulated markets
6.4. Market Share Analysis
CHAP 7. GEOGRAPHICAL ANALYSIS
7.1. Devices market is growing in North America, Europe and Asia Pacific
7.2. North America is the highest drug market for depression
7.2.1. US has the largest patient pool for depression drugs & devices
7.2.2. US market is driven by strict regulations
7.2.3. Mental illness is a major disease in Canada
7.3. Depression is a major concern in Europe
7.3.1. almost 16.7 million people suffer from depression in the UK
7.3.2. Regulations in the United Kingdom
7.3.3. France has the highest rate of depression amongst developed nations
7.3.4. Germany has prevalence rate of 4.5-5% for depression
7.3.5. Spain has strict regulations for depression drugs
7.4. Asia Pacific has a strongly emerging generic drugs market
7.4.1. Approx 60% of the population in China is undiagnosed for depression
7.4.2. India has over 10 million people suffering from depression
7.4.3. Financial burden of depression in Japan amounts to nearly $15 billion
7.4.4. Depression is a common occurring health issue in the age group 12-25 years in Australia
CHAP 8. CORPORATE PROFILING
8.1. Pfizer
8.1.1. Overview
8.1.2. Strategic Analysis
8.1.3. SCOT Analysis
8.2. GlaxoSmithKline
8.2.1. Overview
8.2.2. SCOT Analysis
8.3. Forest Laboratories
8.3.1. Overview
8.3.2. SCOT Analysis
8.4. Abbot Laboratories
8.4.1. Overview
8.4.2. SCOT Analysis
8.5. Eli Lilly and Company
8.5.1. Overview
8.5.2. SCOT Analysis
8.6. Merck Sharp &Dohme
8.6.1. Overview
8.6.2. SCOT Analysis
8.7. Sanofi
8.7.1. Overview
8.7.2. SCOT Analysis
8.8. Neuronetics
8.8.1. Overview
8.8.2. SCOT Analysis
8.9. Teva pharmaceuticals Industries
8.9.1. Overview
8.9.2. SCOT Analysis
8.10. Mayo Clinic
8.10.1. Overview
8.10.2. Mayo Clinic product portfolio in depression therapy
8.10.3. SCOT Analysis
8.11. Sun Pharmaceuticals
8.11.1. Overview
8.11.2. SCOT Analysis
8.12. Brainsway
8.12.1. Overview
8.12.2. SCOT Analysis
8.13. Fisher Wallace
8.13.1. Overview
8.13.2. SCOT Analysis
8.14. MagVentures
8.14.1. Overview
8.15. Lundbeck
8.15.1. Overview
8.15.2. Strategic moves
8.15.3. SCOT Analysis
8.16. BoehringerIngelheim GmbH
8.16.1. Overview
8.16.2. SCOT Analysis
8.17. Roche Holding AG
8.17.1. Overview
8.17.2. Strategic Moves
8.17.3. SCOT Analysis
LIST OF TABLES
TABLE 1 GLOBAL DEPRESSION DRUGS AND DEVICES MARKET 2014-2022 ($ MILLION)
TABLE 2 TIMELINE OF THE BRANDED DRUG EXPIRATION/LAUNCH IN THE U.S.
TABLE 4 GLOBAL ANTIDEPRESSANTS DRUG MARKET2014-2022 ($ MILLION)
TABLE 5 PRICE OF FLOUOXETINE IN DIFFERENT DRUG STORE IN 2012
TABLE 6 PRICE OF PAROXETINE (PAXIL), NORTH AMERICA
TABLE 7 GLOBAL SERTALINE DRUG MARKET2014-2022 ($ MILLION)
TABLE 8 PRICE AND DRUG ATTRIBUTE OF LEXAPRO
TABLE 9 PRICE AND PACKAGE DETAILS OF CYMBALTA
TABLE 10 TABLE: U.S. PRICE OF EFFEXOR OF DIFFERENT STRENGTH
TABLE 11 PRICE OF BUPROPION (WELLBUTRIN)
TABLE 12 PRICE OF TRAZODONE OF DIFFERENT STRENGTH
TABLE 13 PRICE OF TOFRANIL OF DIFFERENT STRENGTH
TABLE 14 PRICE OF TRANYLCYPROMINE (PARNATE)
TABLE 15 GLOBAL VIRTUAL REALITY IN HEALTHCARE MARKET 2014-2022 ($ MILLION)
TABLE 16 DIFFERENCE BETWEEN MALE AND FEMALE DEPRESSION BEHAVIOR
TABLE 17 GLOBAL DEPRESSION DRUGS AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 18 NORTH AMERICA DEPRESSION DRUGS AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 19 FRANCE HAS THE HIGHEST PREVALENCE RATE IN EU IN (2014)
TABLE 20 EUROPEAN DEPRESSION THERAPY AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 21 ASIA PACIFIC DEPRESSION DRUGS AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 22 PFIZER PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 23 GLAXOSMITHKLINE PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 24 FOREST LABORATORIES PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 25 ABBOT LABORATORIES’ PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 26 ELI LILLY AND COMPANY PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 27 SANOFI PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 28 NEURONETICS PRODUCTS PORTFOLIO IN DEPRESSION THERAPY
TABLE 29 TEVA PHARMACEUTICALS INDUSTRIES PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 30 MAGVENTURES PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 31 LUNDBECK PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 32 ROCHE AG PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 1 GLOBAL DEPRESSION DRUGS AND DEVICES MARKET 2014-2022 ($ MILLION)
TABLE 2 TIMELINE OF THE BRANDED DRUG EXPIRATION/LAUNCH IN THE U.S.
TABLE 4 GLOBAL ANTIDEPRESSANTS DRUG MARKET2014-2022 ($ MILLION)
TABLE 5 PRICE OF FLOUOXETINE IN DIFFERENT DRUG STORE IN 2012
TABLE 6 PRICE OF PAROXETINE (PAXIL), NORTH AMERICA
TABLE 7 GLOBAL SERTALINE DRUG MARKET2014-2022 ($ MILLION)
TABLE 8 PRICE AND DRUG ATTRIBUTE OF LEXAPRO
TABLE 9 PRICE AND PACKAGE DETAILS OF CYMBALTA
TABLE 10 TABLE: U.S. PRICE OF EFFEXOR OF DIFFERENT STRENGTH
TABLE 11 PRICE OF BUPROPION (WELLBUTRIN)
TABLE 12 PRICE OF TRAZODONE OF DIFFERENT STRENGTH
TABLE 13 PRICE OF TOFRANIL OF DIFFERENT STRENGTH
TABLE 14 PRICE OF TRANYLCYPROMINE (PARNATE)
TABLE 15 GLOBAL VIRTUAL REALITY IN HEALTHCARE MARKET 2014-2022 ($ MILLION)
TABLE 16 DIFFERENCE BETWEEN MALE AND FEMALE DEPRESSION BEHAVIOR
TABLE 17 GLOBAL DEPRESSION DRUGS AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 18 NORTH AMERICA DEPRESSION DRUGS AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 19 FRANCE HAS THE HIGHEST PREVALENCE RATE IN EU IN (2014)
TABLE 20 EUROPEAN DEPRESSION THERAPY AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 21 ASIA PACIFIC DEPRESSION DRUGS AND DEVICE MARKET 2014-2022 ($ MILLION)
TABLE 22 PFIZER PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 23 GLAXOSMITHKLINE PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 24 FOREST LABORATORIES PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 25 ABBOT LABORATORIES’ PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 26 ELI LILLY AND COMPANY PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 27 SANOFI PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 28 NEURONETICS PRODUCTS PORTFOLIO IN DEPRESSION THERAPY
TABLE 29 TEVA PHARMACEUTICALS INDUSTRIES PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 30 MAGVENTURES PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 31 LUNDBECK PRODUCT PORTFOLIO IN DEPRESSION THERAPY
TABLE 32 ROCHE AG PRODUCT PORTFOLIO IN DEPRESSION THERAPY
LIST OF FIGURES
FIGURE 1 DEPRESSION PREVALANCE-FACT SHEET
FIGURE 2 Worldwide Prevalence of depression by age and gender in 2013
FIGURE 3 High rate of depression in American Indian and Alaska Native –12 month prevalence of major depressive episode among U.S. adults (2012)
FIGURE 4 Lifetime prevalence RATE OF DEPRESSION IN US ADULTS, 2012
FIGURE 5 Dysthymia PATIENTS BY TREATMENT
FIGURE 6 Value Chain of Antidepressant drugs
FIGURE 7 Value Chain Analysis for Device Market
FIGURE 8 CAUSES OF DEPRESSION-(FACTORS BY PERCENTAGE, 2013)
FIGURE 9 Branded Antidepressant drug sales in $million (2003-2012)
FIGURE 10 Global Antidepressants drug market in $million (2013-2021)
FIGURE 11 Savings through generic drug usage in the United States in $billion (2004-2013)
FIGURE 12 Side effects of antidepressants
FIGURE 13 Global Flouoxetine market, 2013-2017, (in $million)
FIGURE 14 Global Escilatopram drug market, 2013-2021 (in $million)
FIGURE 15 Price of Citalopram (Celexa)
FIGURE 16 Global Duloexitine market, 2013-2021, (in $million)
FIGURE 17 Global Venlafexine drug market, 2013-2021, ($million)
FIGURE 18 Global Transcranial Magnetic Stimulation Market, 2013-2021(in $million)
FIGURE 19 Global Deep Brain Stimulation Market, 2013-2021, (in $million)
FIGURE 20 Global Vagus Nerve Stimulation Market, 2013-2021(in $million)
FIGURE 21 coMPARISON OF MALE AND FEMALE DEPRESSION
FIGURE 22 Market Share of major antidepressants in 2021 (%)
FIGURE 23 Market Share of antidepressants drug manufacturers (percentage of sales), 2014
FIGURE 24 GEOGRAPHICAL DISTRIBUTION OF prevalence rate of depression, 2013
FIGURE 25 Devices Market (percentage sales) to be the largest in 2021
FIGURE 26 The U.S. depression therapy market, 2013-2021 ($million)
FIGURE 27 Canada depression therapy market, 2013-2021, ($million)
FIGURE 28 European depression treatment device and therapy market, 2013-2021 ($million)
FIGURE 29 Devices market will double (percentage sales) in 2021 from 2013
FIGURE 30 Total cost of mental illness in England (in $)
FIGURE 31 United Kingdom depression therapy market, 2013-2021 ($million)
FIGURE 32 France depression therapy market, 2013-2021 ($million)
FIGURE 33 Germany depression therapy market, 2013-2021 ($million)
FIGURE 34 Spain depression therapy market, 2013-2021 ($million)
FIGURE 35 China depression therapy market, 2013-2021, ($million)
FIGURE 36 India depression therapy market, 2013-2021, ($million)
FIGURE 37 Japan depression therapy market, 2013-2021, ($million)
FIGURE 38 Australia depression Therapy market, 2013-2021, ($million)
FIGURE 39 Sun Pharmaceuticals products portfolio in depression therapy
FIGURE 40 Brainsway product portfolio in depression therapy
FIGURE 41 Fisher Wallace product portfolio in depression therapy
COMPANIES MENTIONED
1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
FIGURE 1 DEPRESSION PREVALANCE-FACT SHEET
FIGURE 2 Worldwide Prevalence of depression by age and gender in 2013
FIGURE 3 High rate of depression in American Indian and Alaska Native –12 month prevalence of major depressive episode among U.S. adults (2012)
FIGURE 4 Lifetime prevalence RATE OF DEPRESSION IN US ADULTS, 2012
FIGURE 5 Dysthymia PATIENTS BY TREATMENT
FIGURE 6 Value Chain of Antidepressant drugs
FIGURE 7 Value Chain Analysis for Device Market
FIGURE 8 CAUSES OF DEPRESSION-(FACTORS BY PERCENTAGE, 2013)
FIGURE 9 Branded Antidepressant drug sales in $million (2003-2012)
FIGURE 10 Global Antidepressants drug market in $million (2013-2021)
FIGURE 11 Savings through generic drug usage in the United States in $billion (2004-2013)
FIGURE 12 Side effects of antidepressants
FIGURE 13 Global Flouoxetine market, 2013-2017, (in $million)
FIGURE 14 Global Escilatopram drug market, 2013-2021 (in $million)
FIGURE 15 Price of Citalopram (Celexa)
FIGURE 16 Global Duloexitine market, 2013-2021, (in $million)
FIGURE 17 Global Venlafexine drug market, 2013-2021, ($million)
FIGURE 18 Global Transcranial Magnetic Stimulation Market, 2013-2021(in $million)
FIGURE 19 Global Deep Brain Stimulation Market, 2013-2021, (in $million)
FIGURE 20 Global Vagus Nerve Stimulation Market, 2013-2021(in $million)
FIGURE 21 coMPARISON OF MALE AND FEMALE DEPRESSION
FIGURE 22 Market Share of major antidepressants in 2021 (%)
FIGURE 23 Market Share of antidepressants drug manufacturers (percentage of sales), 2014
FIGURE 24 GEOGRAPHICAL DISTRIBUTION OF prevalence rate of depression, 2013
FIGURE 25 Devices Market (percentage sales) to be the largest in 2021
FIGURE 26 The U.S. depression therapy market, 2013-2021 ($million)
FIGURE 27 Canada depression therapy market, 2013-2021, ($million)
FIGURE 28 European depression treatment device and therapy market, 2013-2021 ($million)
FIGURE 29 Devices market will double (percentage sales) in 2021 from 2013
FIGURE 30 Total cost of mental illness in England (in $)
FIGURE 31 United Kingdom depression therapy market, 2013-2021 ($million)
FIGURE 32 France depression therapy market, 2013-2021 ($million)
FIGURE 33 Germany depression therapy market, 2013-2021 ($million)
FIGURE 34 Spain depression therapy market, 2013-2021 ($million)
FIGURE 35 China depression therapy market, 2013-2021, ($million)
FIGURE 36 India depression therapy market, 2013-2021, ($million)
FIGURE 37 Japan depression therapy market, 2013-2021, ($million)
FIGURE 38 Australia depression Therapy market, 2013-2021, ($million)
FIGURE 39 Sun Pharmaceuticals products portfolio in depression therapy
FIGURE 40 Brainsway product portfolio in depression therapy
FIGURE 41 Fisher Wallace product portfolio in depression therapy
COMPANIES MENTIONED
1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
